1. Home
  2. CUK vs ONC Comparison

CUK vs ONC Comparison

Compare CUK & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carnival Plc ADS ADS

CUK

Carnival Plc ADS ADS

HOLD

Current Price

$24.39

Market Cap

34.2B

ML Signal

HOLD

ONC

BeiGene Ltd. American Depositary Shares

HOLD

Current Price

$321.76

Market Cap

34.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUK
ONC
Founded
1972
2010
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2B
34.8B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
CUK
ONC
Price
$24.39
$321.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
18
12
Target Price
$33.67
$369.50
AVG Volume (30 Days)
1.9M
327.3K
Earning Date
12-22-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
61.65
N/A
EPS
1.94
0.58
Revenue
$26,230,000,000.00
$4,972,687,000.00
Revenue This Year
$9.50
$895.40
Revenue Next Year
$3.88
$22.04
P/E Ratio
$12.59
$551.71
Revenue Growth
7.15
50.43
52 Week Low
$13.65
$170.99
52 Week High
$29.80
$385.22

Technical Indicators

Market Signals
Indicator
CUK
ONC
Relative Strength Index (RSI) 51.60 43.15
Support Level $23.34 $310.11
Resistance Level $24.11 $340.98
Average True Range (ATR) 0.74 12.19
MACD 0.15 -3.50
Stochastic Oscillator 90.08 21.42

Price Performance

Historical Comparison
CUK
ONC

About CUK Carnival Plc ADS ADS

Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

Share on Social Networks: